22 results
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
, standards for the manufacture, processing, packaging, testing, transportation, handling and holding of drug products, as set forth in the FDCA
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
, standards for the manufacture, processing, packaging, testing, transportation, handling and holding of drug products, as set forth in the FDCA
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping … must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected
424B3
rloy4
31 Mar 22
Prospectus supplement
11:42am
POS AM
710 1jwupnvl
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
EX-10.1
9k8azs8f269 uizvxxl
12 Nov 21
Prospectus supplement
8:41am
424B3
zpyfergx
5 Aug 21
Prospectus supplement
4:26pm
424B3
wtjneiy 7muuijh
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
7kbzrwv9cee0a
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.14
22ohy
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.19
4ovzmxb6fk1
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.14
yy54cczpq fc
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm